Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-16 · accession 0001104659-23-072606 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-20 | 2023-06-16 | NVCT | Kaplan Matthew L. | Dir | A - Grant | $0.00 | +18.0K | 53.8K | +50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-16 | A | A | 18,000 | $0.00 | 53,760 | D | — | — | (F1) The 18,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the board on such dates. |